Text size A - A+

Bausch + Lomb becomes division of Valeant

Valeant Pharmaceuticals International, Inc., (NYSE: VRX) (TSX: VRX) completed its acquisition of Bausch + Lomb on August 5, 2013. Bausch + Lomb will retain its name and become a division of Valeant. Valeant's existing ophthalmology businesses will be integrated into the Bausch + Lomb division, creating a global eye health platform with estimated pro forma 2013 net revenue of more than $3.5 billion. The united business has a vast eye care product portfolio and a full array of innovative, late stage over-the-counter, prescription and ophthalmic surgery products in the development pipeline. 


Click here to read the news release.